The estimated Net Worth of Edgardo Jr Baracchini is at least $320 mil dollars as of 9 August 2018. Edgardo Baracchini owns over 50,000 units of INmune Bio stock worth over $80,622 and over the last 11 years Edgardo sold INMB stock worth over $239,528.
Edgardo has made over 31 trades of the INmune Bio stock since 2015, according to the Form 4 filled with the SEC. Most recently Edgardo exercised 50,000 units of INMB stock worth $552,500 on 9 August 2018.
The largest trade Edgardo's ever made was exercising 50,000 units of INmune Bio stock on 9 August 2018 worth over $552,500. On average, Edgardo trades about 4,945 units every 28 days since 2014. As of 9 August 2018 Edgardo still owns at least 12,941 units of INmune Bio stock.
You can see the complete history of Edgardo Baracchini stock trades at the bottom of the page.
Edgardo's mailing address filed with the SEC is C/O INMUNE BIO INC,, 225 NE MIZNER BLVD., SUITE 640, BOCA RATON,, FL, 33432.
Over the last 5 years, insiders at INmune Bio have traded over $5,236,202 worth of INmune Bio stock and bought 82,618 units worth $534,813 . The most active insiders traders include Linda F Powers, Edgardo Jr Baracchini, eInc Xencor. On average, INmune Bio executives and independent directors trade stock every 51 days with the average trade being worth of $117,087. The most recent stock trade was executed by Scott Juda on 25 June 2024, trading 5,000 units of INMB stock currently worth $36,350.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio executives and other stock owners filed with the SEC include: